82 related articles for article (PubMed ID: 28565974)
21. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
[TBL] [Abstract][Full Text] [Related]
22. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
23. Interactive anticancer effect of nanomicellar curcumin and galbanic acid combination therapy with some common chemotherapeutics in colon carcinoma cells.
Jafari A; Teymouri M; Ebrahimi Nik M; Abbasi A; Iranshahi M; Hanafi-Bojd MY; Jafari MR
Avicenna J Phytomed; 2019; 9(3):237-247. PubMed ID: 31143691
[TBL] [Abstract][Full Text] [Related]
24. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
25. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
26. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
[TBL] [Abstract][Full Text] [Related]
27. Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2.
Grässlin A; Amoreira C; Baldridge KK; Robinson JA
Chembiochem; 2009 May; 10(8):1360-8. PubMed ID: 19408261
[TBL] [Abstract][Full Text] [Related]
28. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
29. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
[TBL] [Abstract][Full Text] [Related]
30. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
[TBL] [Abstract][Full Text] [Related]
31. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
[TBL] [Abstract][Full Text] [Related]
32. Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells.
Wu X; Zhu Y; Huang W; Li J; Zhang B; Li Z; Yang X
Adv Sci (Weinh); 2018 Aug; 5(8):1700859. PubMed ID: 30128223
[TBL] [Abstract][Full Text] [Related]
33. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model.
Smith JA; Mathew L; Burney M; Nyshadham P; Coleman RL
Gynecol Oncol; 2016 May; 141(2):357-363. PubMed ID: 26946092
[TBL] [Abstract][Full Text] [Related]
34. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.
Brouckaert P; Takahashi N; van Tiel ST; Hostens J; Eggermont AM; Seynhaeve AL; Fiers W; ten Hagen TL
Int J Cancer; 2004 Apr; 109(3):442-8. PubMed ID: 14961585
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of PEGylated nanoliposomes containing crocin in mice bearing C26 colon carcinoma.
Rastgoo M; Hosseinzadeh H; Alavizadeh H; Abbasi A; Ayati Z; Jaafari MR
Planta Med; 2013 Apr; 79(6):447-51. PubMed ID: 23539350
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermia and liposomal encapsulated doxorubicin.
Ben-Yosef R; Gipps M; Zeira M
Isr Med Assoc J; 2003 Jun; 5(6):407-9. PubMed ID: 12841010
[TBL] [Abstract][Full Text] [Related]
37. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.
Ogawara K; Un K; Minato K; Tanaka K; Higaki K; Kimura T
Int J Pharm; 2008 Jul; 359(1-2):234-40. PubMed ID: 18448289
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
39. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.
Seynhaeve ALB; Dicheva BM; Hoving S; Koning GA; Ten Hagen TLM
J Control Release; 2013 Nov; 172(1):330-340. PubMed ID: 24012486
[TBL] [Abstract][Full Text] [Related]
40. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
